Pamidronate [3-amino-1-hydroxypropylidene-1,1-bisphosphonate (APD)] was the first nitrogen-containing bisphosphonate (N-BP) investigated in clinical studies. In contrast to other clinically used bisphosphonates, pamidronate was discovered and its properties were initially studied in an Academic Institution. On the occasion of the 50th Anniversary of the first publications on the biological effects of bisphosphonates, I review in this article the contribution of Leiden investigators to the development of pamidronate that led to the recognition of the significance of the Nitrogen atom in the side chain of bisphosphonates for their action on bone resorption and to the formulation of principles for the use of N-BPs in the management of patients with different skeletal disorders.

中文翻译：

---

帕米膦酸盐：含氮双膦酸盐药理学模型化合物；莱顿的历史视角

帕米膦酸盐 [3-amino-1-hydroxypropylidene-1,1-bisphosphonate (APD)] 是第一个在临床研究中研究的含氮双膦酸盐 (N-BP)。与其他临床使用的双膦酸盐相比，帕米膦酸盐被发现并最初在学术机构中进行了研究。在双膦酸盐生物学效应首次发表 50 周年之际，我在这篇文章中回顾了莱顿研究人员对帕米膦酸盐开发的贡献，这些贡献导致人们认识到了双膦酸盐侧链中氮原子的重要性。双膦酸盐对骨吸收的作用以及制定使用 N-BP 治疗不同骨骼疾病患者的原则。